Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Fizazi K, et al. Among authors: herrmann k. Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4. Lancet Oncol. 2023. PMID: 37269841 Free PMC article. Clinical Trial.
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors.
Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taïeb D, Kjaer A. Hope TA, et al. Among authors: herrmann k. J Nucl Med. 2023 Feb;64(2):204-210. doi: 10.2967/jnumed.122.264860. J Nucl Med. 2023. PMID: 36725249 Free article. No abstract available.
Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. Djaïleb L, et al. Among authors: herrmann k. Eur Urol. 2023 Dec;84(6):588-596. doi: 10.1016/j.eururo.2023.06.022. Epub 2023 Jul 21. Eur Urol. 2023. PMID: 37482512 Clinical Trial.
Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, Unterrainer LM, Fendler WP, Rettig M, Eiber M, Hofman MS, Hadaschik B, Herrmann K, Czernin J, Calais J, Benz MR. Farolfi A, et al. Among authors: herrmann k. J Nucl Med. 2024 Mar 1;65(3):438-445. doi: 10.2967/jnumed.123.266391. J Nucl Med. 2024. PMID: 38238041
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. Weber M, et al. Among authors: herrmann k. Eur Urol. 2024 Jun;85(6):511-516. doi: 10.1016/j.eururo.2024.01.019. Epub 2024 Mar 15. Eur Urol. 2024. PMID: 38490855 Free article.
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
Nikitas J, Lam E, Booker KA, Fendler WP, Eiber M, Hadaschik B, Herrmann K, Hirmas N, Lanzafame H, Stuschke M, Czernin J, Steinberg ML, Nickols NG, Kishan AU, Calais J. Nikitas J, et al. Among authors: herrmann k. J Nucl Med. 2024 Jul 1;65(7):1076-1079. doi: 10.2967/jnumed.123.267004. J Nucl Med. 2024. PMID: 38664019 Clinical Trial.
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study.
Karpinski MJ, Hüsing J, Claassen K, Möller L, Kajüter H, Oesterling F, Grünwald V, Umutlu L, Kleesiek J, Telli T, Merkel-Jens A, Hüsing A, Kesch C, Herrmann K, Eiber M, Hoberück S, Meyer PT, Kind F, Rahbar K, Schäfers M, Stang A, Hadaschik BA, Fendler WP. Karpinski MJ, et al. Among authors: herrmann k. Lancet Oncol. 2024 Sep;25(9):1188-1201. doi: 10.1016/S1470-2045(24)00326-7. Epub 2024 Jul 29. Lancet Oncol. 2024. PMID: 39089299 Free article.
Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers.
Sollini M, Calais J, Chiti A, Emmett L, Fanti S, Fendler W, Herrmann K, Hope TA, Sartor O, Shuch B, Tagawa S, Hofman MS. Sollini M, et al. Among authors: herrmann k. Eur Urol. 2024 Oct 19:S0302-2838(24)02641-1. doi: 10.1016/j.eururo.2024.09.036. Online ahead of print. Eur Urol. 2024. PMID: 39428326 Review.
1,404 results